Clinical research sites participating in the BRITE trial include:
The BRITE trial is currently enrolling patients at most of the trial sites and is open to men and women between ages 21-75 who have been diagnosed with major depression with the most recent episode lasting two or more weeks, and who are not currently on a stable medication regimen.
The BRITE trial represents an important milestone for Aspect to develop a better understanding of the role and value of Aspect's brain assessment technology in helping clinicians improve the care of patients suffering from depression," said Philip Devlin, vice president and general manager of Aspect's neuroscience division.
We remain confident in Aspect's expertise and we look forward to working with Aspect to support the BRITE trial and to ultimately introduce innovative products that address this significant clinical need.
Supplemental material about the BRITE trial for the conference call is available on the Investors section of the company Web site http://investor.